Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Stopped early · Phase 1

Conditions studied: Myelodysplastic Syndromes

In brief

The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

Key facts

Study ID

NCT04810611

Run by

Novartis Pharmaceuticals

People needed

33

Starts

2021-06-18

Expected to finish

2024-04-19

Last updated by the study team

2025-10-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City Of Hope National Med Center Oncology — Duarte, California, United States
• H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Massachusetts General Hospital . — Boston, Massachusetts, United States
• The Ohio State University Wexner Medical Center . — Columbus, Ohio, United States
• MD Anderson Cancer Center/University of Texas MD Anderson — Houston, Texas, United States
• Novartis Investigative Site — Prahran, Victoria, Australia
• Novartis Investigative Site — Tel Aviv, Israel
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Salamanca, Castille and León, Spain
• Novartis Investigative Site — Barcelona, Catalonia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.